Press releases

Press releases.

Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer

March 14th 2023
press releases

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

February 6th 2023
press releases

Immutep Quarterly Activities Report

January 30th 2023
press releases
more

Investor updates

Investor updates.

Investor Update - November 2022

November 17th 2022
investor updates

Investor Update ASCO 2022 Special Edition June 2022

June 17th 2022
investor updates

Investor Update - February 2022

February 18th 2022
investor updates
more

Analyst reports

Analyst reports.

Maxim Group - New P2/3 AIPAC-003 Study Initiated with More Aggressive Dosing and OS Primary in Breast Cancer; Rating Buy, $8 tgt (Analyst: Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

March 14th 2023
analyst reports

CLSA - Immutep: Defining year. Cash-runway through late stage head & neck readout and Lung Ph3 start. Retain Buy, A$1.25 tgt (Andrew Paine)

For a copy of this analyst report please contact your CLSA advisor

March 7th 2023
analyst reports

Petra Capital - Immutep Limited (IMM) - Accelerating clinical and manufacturing work (Analyst: Tanushree Jain)

For a copy of this analyst report please contact your Petra advisor

February 28th 2023
analyst reports
more


E-MAIL UPDATES

registration.

Please fill out the registration form below to receive updates and announcements by e-mail.